Abstract
P01.03 Phase 1 Study of Patritumab Deruxtecan (HER3-DXd; U3-1402) in Combination with Osimertinib in Patients with Locally Advanced or Metastatic EGFR-mutated NSCLC
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have